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Abstract
In this study, we improve on current autoantigen discovery approaches by creating a synthetic
representation of the complete human proteome, the T7 “peptidome” phage display library (T7-
Pep), and use it to profile the autoantibody repertoires of individual patients. We provide methods
for 1) designing and cloning large libraries of DNA microarray-derived oligonucleotides encoding
peptides for display on bacteriophage, and 2) analysis of the peptide libraries using high
throughput DNA sequencing. We applied phage immunoprecipitation sequencing (PhIP-Seq) to
identify both known and novel autoantibodies contained in the spinal fluid of three patients with
paraneoplastic neurological syndromes. We also show how our approach can be used more
generally to identify peptide-protein interactions and point toward ways in which this technology
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twill be further developed in the future. We envision that PhIP-Seq can become an important new
tool in autoantibody analysis, as well as proteomic research in general.
Keywords
Synthetic biology; proteomics; phage display; humoral autoimmunity; paraneoplastic neurological
disorder; protein-protein interactions
INTRODUCTION
Vertebrate immune systems have evolved sophisticated genetic mechanisms to generate
antibody repertoires, which are combinatorial libraries of affinity molecules capable of
distinguishing between self and non-self. Recent data highlight the delicate balance in higher
mammals between energy utilization, robust immune defense against pathogens, and
autoimmunity1. In humans, loss of tolerance to self-antigens results in a number of diseases
including type I diabetes, multiple sclerosis, and rheumatoid arthritis. Knowledge of the self
antigens involved in autoimmune processes is not only important for understanding the
disease etiology, but can also be used to develop accurate diagnostic tests. In addition,
physicians may someday utilize antigen-specific therapies to target auto-reactive immune
cells for destruction or quiescence.
Traditional approaches to identification of autoantibody targets largely rely on expression of
fragmented cDNA libraries. Important technical limitations of this method include the small
fraction of clones expressing in-frame coding sequences (with a lower boundary of 6%)2,
and the highly skewed representation of differentially expressed cDNAs. Nevertheless,
expression cloning has led to the discovery of many important autoantigens3-5. Strides have
been made to improve peptide display systems6, 7, but there remains an important unmet
need for better display libraries and methods to analyze binding interactions.
Here, we have constructed the first synthetic representation of the complete human
proteome, which we have engineered for display as peptides on the surface of T7 phage.
This T7 “peptidome” library (T7-Pep) was extensively characterized and found to be both
faithful to its in silico design and uniform in its representation. We combined our T7-Pep
library with high-throughput DNA sequencing to identify autoantibody-peptide interactions,
a method we call phage immunoprecipitation sequencing (PhIP-Seq). This approach
provides several advantages over traditional methods, including comprehensive and
unbiased proteome representation, peptide enrichment quantification, and a streamlined,
multiplexed protocol requiring just one round of enrichment. We have applied PhIP-Seq to
interrogate the autoantibody repertoire in the spinal fluid of patients with neurological
autoimmunity and identified both known and novel autoantigens. We further demonstrate
how PhIP-Seq can also be used more generally to identify peptide-protein interactions.
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Construction and Characterization of T7-Pep
We sought to create a synthetic representation of the human proteome. We began by
extracting all open reading frame (ORF) sequences available from build 35.1 of the human
genome (24,239; 23% of which had “predicted” status). When there were multiple isoforms
of the same protein, we randomly selected one representative ORF. We modified the codon
usage by eliminating restriction sites used for cloning and by substituting very low
abundance codons in E. coli with more abundant synonymous codons. We parsed this
database into sequences of 108 nucleotides encoding 36 amino acid tiles with an overlap of
seven residues between consecutive peptides (Fig. 1a), the estimated size of a linear epitope.
Finally, the stop codon of each ORF was removed so that all peptides could be cloned in-
frame with a C-terminal FLAG tag.
The final library design includes 413,611 peptides spanning the entire coding region of the
human genome. The peptide-coding sequences were synthesized as 140-mer
oligonucleotides with primer sequences on releasable DNA microarrays in 19 pools of
22,000 oligos each, PCR-amplified and cloned into a derivative of the T7Select 10-3b phage
display vector (Novagen; Fig. 1b i and Supplementary Methods). We also generated two
additional libraries comprising the N-terminal and C-terminal peptidomes (T7-NPep, T7-
CPep), which encode only the first and last 24 codons from each ORF.
The extent of vector re-ligation, multiple insertions, mutations, and correct in-frame phage-
displayed peptides was determined by plaque PCR analysis (Supplementary Table 1), clone
sequencing (Fig. 1c), and FLAG expression (Supplementary Table 2) of randomly sampled
phage from all subpools. Sequencing revealed that 83% of the inserts lacked frameshifting
mutations. These data indicate that a much greater fraction of in-frame, ORF-derived
peptides is expressed by our synthetic libraries compared to those constructed from cDNA
(Table 1).
After combining 5 × 108 phage from each subpool and amplifying the final library, Illumina
sequencing was performed at a median depth of 45-fold coverage (Fig. 1d) and detected
91.2% of the expected clones. Chao1 analysis was performed to estimate the actual library
complexity (assuming infinite sampling), which predicted that >91.8% of the library was
represented (Supplementary Fig. 1)8. In addition, T7-Pep is highly uniform, with 78% of the
library members within 10-fold abundance (having been sequenced between 10 and 100
times). These data suggest that our library encodes a much more complete and uniform
representation of the human proteome than can otherwise be achieved with existing
technologies (Table 1).
We next optimized a phage immunoprecipitation protocol for detecting antibody-peptide
interactions within complex mixtures (Supplementary Fig. 2). By combining this protocol
with T7-Pep and deep sequencing DNA analysis, we have developed a new method to
quantitatively profile autoantibody repertoires in patients (Fig. 1b).
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Cancers often elicit cellular and humoral immune responses against tumor antigens which
may limit disease progression9. In rare cases, tumor immunity can recognize central nervous
system (CNS) antigens, triggering a devastating autoimmune process called paraneoplastic
neurological disorder (PND). Clinical presentations of PND are heterogeneous and correlate
with the CNS autoantigens involved. PND has served as a model for CNS autoimmunity,
and the application of phage display to PND autoantigen discovery has met with much
success3, 10.
To assess the performance of PhIP-Seq for autoantigen discovery, we examined a sample of
cerebrospinal fluid (CSF) from a 63-year-old female (Patient A) with non-small cell lung
cancer (NSCLC) who presented with a PND syndrome and was found to have anti-NOVA
autoantibodies11. The NOVA autoantigen (neurooncological ventral antigen, or “Ri”) is
commonly targeted in PND triggered by lung or gynecological cancers, and results in ataxia
with or without opsoclonus/myoclonus. A concentration of 2 μg/ml of CSF antibody was
spiked with 2 ng/ml of an antibody specific to SAPK4 (positive control) to monitor
enrichment of the targeted peptide on protein A/G beads. Despite extensive washing,
298,667 unique clones (83% of the input library) were found in the immunoprecipitate. A
significant correlation was observed between the abundance of input clones and
immunoprecipitated clones (Fig. 2a), likely due to weak nonspecific interactions with the
beads.
To approximate the expected distribution of IP'ed clones’ abundances, we employed a two-
parameter generalized Poisson (GP) model (as recently demonstrated for RNA-seq data12)
and found that this distribution family fits the data well at various input abundances (Fig.
2b). We calculated the GP parameter values for each input abundance level13 and regressed
these parameters to form our null model for the calculation of enrichment significance (p-
values) of each clone (Fig. 2c and Supplementary Methods). Comparing the two PhIP-Seq
replicates revealed that the most significantly enriched clones were the same in both replicas
(Fig. 2d), highlighting the assay`s reproducibility. This contrasts dramatically with a
comparison of clones enriched by two different patients (Supplementary Fig. 3). Performing
PhIP-Seq in the absence of patient antibodies identified phage capable of binding to the
protein A/G beads. We thus defined Patient A positive clones as those clones with a
reproducible Log10 p-value greater than a cutoff (Fig. 2d, dashed red line), but not
significantly enriched on beads alone (P < 10-3). Patient A positives included the expected
SAPK4-targeted positive control peptide (P < 10-15), the expected NOVA1 autoantigen (P <
10-15), and six additional candidate autoantigens (Table 2).
We tested three of these predictions by expressing full-length TGIF2LX, DBR1 and PCDH1
in 293T cells and immunoblotting with patient CSF. TGIF2LX (TGFB-Induced factor
homeobox 2-like, X-linked) was confirmed as a novel autoantigen, as we detected strong
immunoreactivity at the expected molecular weight (Fig. 3a). Full-length DBR1 and
PCDH1, while expressed well in 293T cells (not shown), were not detected by CSF
antibodies. We observed two bands in the untransfected lysate migrating at approximately
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t50 and 62 KDa, representing endogenously expressed proteins that correspond either to
untested candidates or to false negatives of the PhIP-Seq assay.
Strikingly, the hypothetical protein LOC26080 had seven distinct peptides that were
significantly enriched, and they all appeared to share a nine residue repetitive motif. We
used MEME software14 to characterize this motif, which represents the likely epitope
recognized by Patient A's autoantibodies (Fig. 3b).
PhIP-Seq analysis of spinal fluid from PND patients with uncharacterized autoantibodies
Having established that PhIP-Seq could reliably identify known and novel autoantigens, we
examined CSF from two additional patients who had suggestive PND presentations but
tested negative for a panel of commercially available PND autoantigens. Patient B was a 59-
year-old female with NSCLC, who presented with dysarthria, ataxia, head titubation and
muscular rigidity. PhIP-Seq analysis yielded three particularly interesting candidate
autoantigens: TGIF2LX, CTAG2 (cancer/testis antigen 2), and GAD65 (glutamate
decarboxylase 2) (Table 2). Both TGIF2LX and CTAG2 were confirmed by immunoblotting
(Fig. 3c). Surprisingly, Patient B, like Patient A, was auto-reactive against TGIF2LX. The
enriched peptide was distinct from, but overlapped the peptide enriched by Patient A (Fig.
3d).
CTAG2 is a member of a family of cancer/testis antigen (CTAG) proteins that are normally
germ cell restricted, but frequently expressed in cancers and often elicit anti-tumor immune
responses15. Several reports have described both humoral and cellular immune responses
targeted against CTAG216, 17. TGIF2LX is also testis restricted18, 19 and may be a new
CTAG family member. As a negative control, we found TGIF2LX reactivity to be absent in
the CSF of three patients with non-PND CNS autoimmunity and oligoclonal Ig bands
(Supplementary Fig. 4). Having confirmed TGIF2LX autoreactivity in two NSCLC patients,
we wondered whether it could be a new biomarker for this disease. However, the serum of
15 additional NSCLC patients without PND did not contain TGIF2LX antibodies detectable
by immunoblotting (Supplementary Fig. 5).
Neither CTAG2 nor TGIF2LX is expressed in the brain, and thus are unlikely to explain the
neurological syndrome experienced by Patient B. GAD65, however, is the rate-limiting
enzyme in the synthesis of the inhibitory neurotransmitter GABA. GAD65 is also a well-
characterized autoantigen targeted in the autoimmune disorder Stiff Person Syndrome (SPS;
OMIM ID 184850). Two non-overlapping GAD65 peptides derived from the domain known
to be targeted by pathogenic autoantibodies in SPS patients20, 21 were enriched by Patient
B's CSF. A commercial radioimmunoassay (RIA 81596; Mayo Medical Laboratories),
confirmed the presence of high titer anti-GAD65 autoantibodies (5.12 nmol/L; >250 fold
above the reference range). Surprisingly, direct immunoblotting with Patient B's CSF did not
demonstrate reactivity (Fig. 3c), suggesting that denatured GAD65 epitopes are not
recognized by Patient B's antibodies. Successful immunoprecipitation of GAD65 from the
same cell lysate with CSF confirmed this hypothesis (Fig. 3e).
Patient C, a 59-year-old female with PND secondary to melanoma, had an unusual
presentation that included horizontal gaze palsy. PhIP-Seq analysis of Patient C's CSF
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tyielded five significantly enriched peptides from two homologous members of the tripartite
motif (TRIM) family, TRIM9 and TRIM67 (Table 2). Both candidate autoantigens were
confirmed by immunoblotting lysates from TRIM9- or TRIM67-overexpressing cells (Fig.
3f). TRIM67 is expressed in some normal tissues (including skin) and is often highly
expressed in melanoma19. TRIM9 has recently emerged as a brain-specific E3 ubiquitin
ligase and has been implicated in neurodegenerative disease processes22. Based on their
high degree of homology, our data suggest the possibility that tumor immunity targeting
TRIM67 might have spread to, or cross-reacted with TRIM9 in the CNS (Supplementary
Fig. 6). TRIM9 and TRIM67 autoreactivity was not detected in the CSF of three patients
with non-PND CNS autoimmunity (Supplementary Fig. 4).
In total, 16 of the candidate autoantigens in Table 2 were available to us as full-length
Gateway Entry clones from the ORFeome collection23. Of these, 10 were not confirmed by
immunoblotting or immunoprecipitation of the full-length protein. We wondered whether
this reflected a high rate of false positive discovery inherent to PhIP-Seq, or rather a
requirement that the peptides be presented with intact conformation, as was the case for
GAD65. We synthesized 9 of these 10 candidate T7 clones, plus 2 additional high
confidence T7 clones, for validation in a dot blot assay. Each of these clones exhibited
immunoreactivity above background with the appropriate patients’ spinal fluid as predicted
by the PhIPSeq dataset (Fig. 3g; Supplementary Fig. 7). This finding indicates that PhIP-Seq
analysis can have a low rate of false positive discovery, and supports the hypothesis that the
36 amino acid peptides retain a significant amount of secondary structure during display on
the T7 coat.
PhIP-Seq can be used to identify protein-protein interactions
The utility of T7-Pep is not limited to autoantigen identification. To explore more general
interactions, we have used the library in an in vitro peptide-protein “two-hybrid” interaction
experiment with GST-RPA2 (replication protein A2) as bait for T7-Pep. We were again able
to utilize the generalized Poisson method for determining the significance of phage clones’
enrichment. Whereas GST alone did not significantly enrich any library clones (P < 10-4;
Supplementary Fig. 8), PhIP-Seq with GST-RPA2 robustly identified the N-terminal peptide
from the known interactor SMARCAL1 (P < 10-14, Fig. 4a), among others (Supplementary
Table 3). The enriched SMARCAL1 peptide contains a previously identified motif known to
bind RPA224, 25. Peptides from four proteins known to contain this motif (UNG2, TIPIN,
XPA and RAD52) were significantly disrupted by the positions of the breaks between
peptides (Fig. 4b). One peptide from UNG2 retained most of the motif and that peptide was
correspondingly enriched (P < 10-5), demonstrating the power of this approach to identify
linear interaction motifs.
DISCUSSION
We have developed a new proteomic technology called Phage Immunoprecipitation
Sequencing (PhIP-Seq), which is based on a synthetic phage library (T7-Pep) made to
uniformly express the complete human peptidome on the coat of T7 phage particles.
Combining T7-Pep with high throughput DNA sequencing enables a variety of innovative
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tproteomic investigations. In addition to applications in autoimmune disease, PhIP-Seq can
be utilized to identify peptide-protein interactions and can be a viable alternative to two-
hybrid analyses. From a methodological perspective, the robust single-round enrichment
signals and the ability to adapt the assay to 96-well format suggests the feasibility of
performing automated PhIP-Seq screens on large sets of samples.
Antibodies bind protein antigens by a variety of mechanisms and several studies have
uncovered some general themes underlying these interactions. For instance, antibody
combining surfaces on natively folded proteins tend to be dominated by “discontinuous”
epitopes, which are patches of ~4-14 amino acid side chains formed by two or more
noncontiguous peptides brought into proximity during protein folding26, 27. If the protein is
divided into it's constituent peptides, antibody affinity is expected to decrease due to 1) the
loss of contacts contributed by noncontiguous residues, and 2) the increased entropic costs
of binding a free peptide as opposed to the natively constrained peptide. The degree to
which individual peptides are still able to interact with a given antibody is difficult to
predict, and is expected to vary widely. While our study demonstrates the utility of 36 amino
acid tiles, further work will be required to define the true false negative discovery rate
inherent to the use of T7-Pep. Autoantibodies that target normally inaccessible epitopes have
also been reported, such as those that recognize proteolytic cleavage products28, 29,
misfolded proteins or protein aggregates30, 31. Antigen discovery with full-length, folded
proteins may thus be less sensitive than tiled peptides in some such circumstances.
In our study, performing PhIP-Seq with CSF from a well characterized PND patient (Patient
A), identified a known (NOVA1) and a novel, testis-restricted19 autoantigen (TGIF2LX).
Since we also found anti-TGIF2LX antibodies in the spinal fluid of a second PND patient
with NSCLC, this protein may represent a new cancer-testis antigen family member, and
should be further investigated as a biomarker for PND. PhIP-Seq analysis of CSF from two
PND patients with uncharacterized antibodies (Patients B and C) uncovered likely neuronal
targets of their autoimmune syndromes. In Patient B, high titer anti-GAD65 antibodies
bound two distinct peptides from the region of the protein associated with Stiff Person
Syndrome (SPS). Interestingly, GAD65 targeting in SPS occurs more often in patients
without cancer, raising the possibility that at least part of this neurological syndrome may
have been unrelated to the patient's cancer. This finding highlights the utility of unbiased
antibody profiling to distinguish between deceptively similar disease states32. In Patient C,
we identified TRIM9 as a likely neuronal autoantigen and suggest the possibility of epitope
spreading from tumor-derived TRIM67 as a potential mechanism. It should be noted that
demonstration of a protein's autoreactivity is not evidence for its role in disease
pathogenesis, since the autoantibodies might be incidental in nature, arise due to epitope
spreading, or might simply exhibit non-cognate cross-reactivity.
Several interesting features of the T7-Pep + PhIP-Seq platform emerged during this proof-
of-concept study. We found that patient antibodies targeting GAD65 robustly recognized
two 36 amino acid peptides, but not the corresponding denatured full-length proteins,
indicating that an important degree of conformational information is retained in the peptide
library. Second, for proteins with known crystal structures, using tiled peptides can facilitate
determination of the antibody clonality, as well as the location of the targeted epitope.
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the discovery of epitope motifs. Autoantibodies from Patient A targeted seven peptides from
a repetitive hypothetical protein, and we were thus able to calculate a motif that most likely
represented the antigenic epitope, a task less easily performed with alternative technologies.
T7-Pep could be improved in several ways. The generation of longer oligos will decrease the
complexity of the library, thereby increasing the sampling depth and making it possible to
generate domain libraries that capture more protein-folding units. In addition, PhIP-Seq with
libraries of peptides from human pathogens could permit rapid analysis of antibodies to
infectious agents, thus aiding vaccine research and the diagnosis of infectious diseases.
We have taken a synthetic biological approach to develop a proteomic resource useful in
translational medicine. When combined with high throughput DNA sequencing, our
methodology permits unbiased and quantitative analysis of autoantibody repertoires in
human patients. PhIP-Seq thus complements existing proteomic technologies in the study of
autoimmune processes for which the relevant autoantigens remain unknown.
METHODS
Detailed methods are available in the supplementary online materials at http://
www.nature.com/naturebiotechnology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Construction and characterization of T7-Pep and the PhIP-Seq methodology
(a) The T7-Pep library is made from 413,611 DNA sequences encoding 36 amino acid
peptide tiles that span 24,239 unique ORFs from build 35.1 of the human genome. Each tile
overlaps its neighbors by seven amino acids on each side. (b) The DNA sequences from (a)
were printed as 140-mer oligos on releasable DNA microarrays. (i) After oligo release, the
DNA was PCR-amplified and cloned into a FLAG-expressing derivative of the T7Select
10-3b mid copy phage display system. (ii) The T7-Pep library is mixed with patient samples
containing autoantibodies. (iii) Antibodies and bound phage are captured on magnetic
protein A/G coated beads. (iv) DNA from the immunoprecipitated phage is recovered and
(v) library inserts are PCR-amplified with sequencing adapters. A single nucleotide change
(arrow) is introduced for multiplex analysis. (c) Pie chart showing results of plaque
sequencing of 71 phage from T7-Pep Pool 1 and T7-CPep Pool 1. (d) Histogram plot
showing results from Illumina sequencing of T7-Pep. 78% of the total area lies between the
vertical red lines at 10 and 100 reads, demonstrating the relative uniformity of the library.
Representation of each subpool in T7-Pep (inset) compared to expected (horizontal red line).
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tFigure 2. Statistical analysis of PhIP-Seq data
(a) Scatter plot comparing sequencing reads from T7-Pep input library and from Patient A
immunoprecipitated (IP) phage (Pearson coefficient = 0.435; P ~= 0). Highlighted are all
clones with an input abundance of 50 reads (red), and all clones with an input abundance of
100 reads (blue). The target of the SAPK4 control antibody is highlighted in green. (b)
Histogram plot of sequencing reads from the data highlighted in (a) with corresponding
colors. The curves are fit with a generalized Poisson (GP) distribution. Pmf is the probability
mass function of the corresponding GP distribution and x is the number of IP sequencing
reads. (c) Plots of lambda and theta for each input abundance, calculated using the method
of Consul et al13. Lambda is regressed to its average value (black dashed line) and theta is
linearly regressed (red dashed curve). (d) Scatter plot comparing clone enrichment
significances (as –Log10 p-value) from two independent PhIP-Seq experiments using CSF
Larman et al. Page 12
Nat Biotechnol. Author manuscript; available in PMC 2014 September 19.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tfrom Patient A. Red dashed line shows the cutoff for considering a clone to be significantly
enriched, and the SAPK4 control antibody target is highlighted in green.
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tFigure 3. Validation of full-length PhIP-Seq candidates
(a) Western blot with CSF from Patient A, staining for full-length TGIF2LX-GFP expressed
in 293T cells by transient transfection. Bands corresponding to TGIF2LX-GFP are denoted
by an arrow. (b) ClustalW alignment of the seven significantly enriched hypothetical protein
LOC26080 peptides, and the nine-element MEME-generated recognition motif. (c) Western
blot with CSF from Patient B, staining for indicated full-length proteins expressed in 293T
cells by transient transfection. (d) Bar graph of –Log10 p-values of enrichment for the
indicated TGIF2LX peptides by the three patients. (e) Immunoprecipitation of the GAD65-
GFP from (c) by CSF from Patient B (but not Patient A). (f) Western blot with CSF from
Patient C, staining for indicated full-length proteinss expressed in 293T cells by transient
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ttransfection. (g) Phage lysates from candidate T7 clones were spotted directly onto
nitrocellulose membranes, which were subsequently immunoblotted with patient CSF.
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tFigure 4. PhIP-Seq can identify protein-protein interactions
GST-RPA2 was used to precipitate phage from the T7-Pep library on magnetic glutathione
beads. (a) –Log10 p-values of enrichment were calculated using the generalized Poisson
method. Clones are arranged in increasing input abundance from left to right. The
experiment identified two of the known RPA2 binding partners SMARCAL1 (P < 10-14)
and UNG2 (P < 10-5), highlighted in red. (b) Dependence of peptide enrichment on integrity
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tof RPA2 binding motif. Phage peptides containing the RPA2-binding motif (underlined) are
shown next to their –Log10 p-value of enrichment.
Larman et al. Page 17
Nat Biotechnol. Author manuscript; available in PMC 2014 September 19.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tN
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Larman et al. Page 18
Table 1
Comparison between the T7-Pep + PhIP-Seq approach and current proteomic methods for autoantigen
discovery.
Feature Classic cDNA Phage Display Protein Array T7-Pep + PhIP-Seq
Proteome representation • Incomplete
• Highly skewed distribution
• Small fraction
• Uniform distribution
• Nearly complete
• Uniform distribution
Fraction of clones expressing an
ORF peptide in frame
As low as 6% Up to 100% ~83%
Size of displayed peptides Up to full-length proteins Up to full-length proteins 36 amino acid overlapping tiles
Rounds of selection Requires multiple selection
rounds, which favor more
abundant and faster growing
clones
No selection Single selection, which eliminates clone
growth bias and population bottleneck
Analysis Individual clone sequencing:
• Initial abundance unknown
• Requires population
bottleneck
Microarray scanning:
• Quantitative
• Statistical analysis of
antibody binding
Deep sequencing of library:
• Quantify population before and after a
single round of selection
• Statistical analysis of enrichments
Determination of antibody
polyclonality
Difficult Not possible Often straightforward for antigens of
known crystal structure
Epitope mapping Difficult Not possible Often straightforward
Effort Labor intensive Minimal Minimal
Sample throughput Low Medium Adaptable to 96 well format
Multiplexing capability No No Yes
Cost Low Moderate to high Moderate
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Table 2
PhIP-Seq analysis on CSF from patients with PND and secondary validation
A previously known autoantigen is shown in green. Autoantigens confirmed by any secondary assay are
shown in bold. Confirmation with the full-length protein is indicated by red type. Average of replicate –Log10
p-values are shown in column 2. If multiple peptides from the same ORF are enriched, the average – Log10 p-
value of the most significantly enriched peptide is shown. Secondary validation assay abbreviations: NT = not
tested; WB = western blot of full-length proteins; IP = immunoprecipitation of full-length proteins followed
by western blotting for the GFP tag. RIA = radioimmunoassay; DB = dot blot. Validation assay is followed by
“+” or “–” depending on whether the results were positive or negative.
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